Skip to Content

Superior efficacy of Iptacopan in PNH patients

Oral monotherapy with Iptacopan, a proximal complement inhibitor of factor B, has been compared with the standard of care with eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia. The superior effects of Iptacopan are elaborated by professor Régis Peffault de Latour, in this MEDtalk.

Régis Peffault De Latour

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top